biote (NASDAQ:BTMD) Price Target Cut to $2.00 by Analysts at B. Riley Financial

biote (NASDAQ:BTMD) had its target price decreased by B. Riley Financial from $3.00 to $2.00 in a research report released on Thursday,Benzinga reports. B. Riley Financial currently has a neutral rating on the stock.

A number of other equities research analysts have also recently commented on the stock. TD Cowen lowered their price objective on shares of biote from $3.00 to $2.50 and set a “buy” rating on the stock in a research note on Thursday. Truist Financial set a $5.00 target price on shares of biote in a research report on Wednesday, January 7th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of biote in a report on Monday, December 29th. Finally, National Bank Financial set a $2.50 price objective on shares of biote in a research note on Thursday. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, biote currently has an average rating of “Hold” and a consensus price target of $3.00.

biote Stock Performance

BTMD opened at $1.54 on Thursday. The business’s fifty day moving average is $2.17 and its two-hundred day moving average is $2.64. The company has a market cap of $70.32 million, a price-to-earnings ratio of 2.05 and a beta of 1.14. biote has a one year low of $1.54 and a one year high of $4.75.

biote (NASDAQ:BTMD) last announced its quarterly earnings results on Wednesday, March 11th. The company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.05 by $0.01. The business had revenue of $46.41 million during the quarter, compared to analysts’ expectations of $45.79 million. biote had a negative return on equity of 21.42% and a net margin of 14.07%. On average, analysts predict that biote will post 0.75 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Geode Capital Management LLC boosted its stake in shares of biote by 1.3% during the 4th quarter. Geode Capital Management LLC now owns 620,256 shares of the company’s stock worth $1,613,000 after purchasing an additional 8,016 shares during the last quarter. State Street Corp raised its position in shares of biote by 17.3% in the fourth quarter. State Street Corp now owns 600,114 shares of the company’s stock valued at $1,560,000 after buying an additional 88,402 shares during the last quarter. Hillsdale Investment Management Inc. raised its position in shares of biote by 24.2% in the second quarter. Hillsdale Investment Management Inc. now owns 420,273 shares of the company’s stock valued at $1,689,000 after buying an additional 81,829 shares during the last quarter. Rice Hall James & Associates LLC lifted its stake in shares of biote by 6.1% during the fourth quarter. Rice Hall James & Associates LLC now owns 240,829 shares of the company’s stock valued at $626,000 after buying an additional 13,805 shares during the period. Finally, Renaissance Technologies LLC lifted its stake in shares of biote by 5.7% during the fourth quarter. Renaissance Technologies LLC now owns 203,594 shares of the company’s stock valued at $529,000 after buying an additional 10,900 shares during the period. Institutional investors and hedge funds own 21.68% of the company’s stock.

Key biote News

Here are the key news stories impacting biote this week:

• Positive Sentiment: Q4 results beat expectations: biote reported EPS of ~$0.063 vs. consensus ~$0.05 and revenue of $46.4M vs. ~$45.8M, showing the company can still deliver small upside to estimates. Biote Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Management projects 2026 revenue at or above ~$190M while investing in sales headcount and its technology platform — a sign of growth initiatives that could support longer-term revenue expansion. Biote projects 2026 revenue above $190M
• Neutral Sentiment: Multiple outlets posted earnings-call transcripts and coverage (Seeking Alpha, InsiderMonkey, AOL, Zacks), which increase transparency but don’t by themselves move fundamentals. Q4 2025 Earnings Call Transcript
• Neutral Sentiment: Reports show a flagged increase in reported “short interest” entries but the published figures are zero/erroneous and not meaningful — no clear short-pressure signal from the data provided.
• Negative Sentiment: FY‑2026 revenue guidance of ~$190.0M came in below the consensus (~$195.4M), and management did not provide clear EPS guidance — the revenue shortfall vs. Street expectations is the primary near-term negative catalyst. Biote Corp (BTMD) Q4 2025 Earnings Call Highlights
• Negative Sentiment: Analyst reaction: B. Riley lowered its price target from $3.00 to $2.00 and moved to a “neutral” rating — a fresh negative signal for sentiment and potential selling pressure. B. Riley Lowers Price Target

biote Company Profile

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.